Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

  • End date
    Sep 15, 2030
  • participants needed
  • sponsor
Updated on 4 June 2022
blood transfusion


Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.


Determine the maximum tolerant dose (MTD) based on the safety and tolerability of AT101 and the recommended dose 2 dose (RP2D) in phase 2 trials for patients with recurrent or non-reactive B cell non-Hodgkin lymphoma (B-cell NHL).

Condition B-cell Non Hodgkin Lymphoma
Treatment AT101, AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
Clinical Study IdentifierNCT05338931
Last Modified on4 June 2022


Yes No Not Sure

Inclusion Criteria

B cell non-Hodgkin lymphoma based on WHO classification 2017
incompatible with existing standard therapies or have had disease progression, and whose standard therapies do not currently have available standard therapies due to reasons such as intolerance/inadequacies or rejection
The Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
adequate hematological, kidney, liver, lung, heart and bone marrow function without blood transfusion within two weeks prior to screening
Those with a minimum life expectancy of 12 weeks or more
In women with childbearing, clinical response tests (serum- or ure-hCG) were negatively identified during this trial
Those who have agreed in writing to participate voluntarily in this trial

Exclusion Criteria

Those who have previously had a history of treating homologic autologous hemoblastitis (allogeneic HSCT)
At101/adcidmilisers, anticancer chemotherapy/adcidms for lymphodeletion or those who are hypersensitive to tocilizumab
Those who cannot take autologous blood
Those who have received chemotherapy or radiotherapy, excluding lymphodeletion, within two weeks prior to IP administration
Persons who have not been recovered (CTCAE grade ≤1 or baseline) due to previous treatment
Those who have identified a condition that, at the test's discretion, may affect safety and validation during the trial period
Those who have identified the following forces at the time of screening
Those who have been clinically aware of heart disease within 6 months prior to screening
Those identified as thromboembolic disease, pulmonary embolism or bleeding bleeding diatheses within 6 months prior to screening
Those who have identified a history of malignant tumors other than B-cell non-Hodgkin's lymphoma within five years prior to screening
Those who have undergone major surgery within 4 weeks prior to screening
Those who have undergone non-critical surgery within two weeks prior to screening
Childbearing women or men who do not have the will to use effective contraception for
a longer period of time, either 12 months after clinical trial period and
AT101 administration or when AT101 in the body is not identified
Those who have been administered or applied to other IP/ID within 4 weeks of screening
Those who are addicted to alcohol and/or medication
Those who are unfit or unable to participate in this trial when judged by PI
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note